TESI DOTTORATO MICAELA RANIERI - DSpace - Tor Vergata
TESI DOTTORATO MICAELA RANIERI - DSpace - Tor Vergata
TESI DOTTORATO MICAELA RANIERI - DSpace - Tor Vergata
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
82. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH,<br />
Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ A short term study of<br />
chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's<br />
disease. N Engl J Med 1997; 337: 1029-35<br />
83. Rutgeerts P, D’Haens G, Targan S, Vasilauskas E, Hanauer SB, Present<br />
DH, Mayer L, Van Hogezand RA, Braakman T, De Woody KL, Schaible TF,<br />
Van Deventer SJ. Efficacy and safety of retreatment with anti tumor necrosis<br />
factor antibody (infliximab) to mantain remission in Crohn’s disease.<br />
Gastroenterology 1999; 117: 761-769<br />
84. Rutgeerts P, Colombel J, Schreiber S, Mayer L, Lichtenstein G,<br />
Rachmilewicz D, Wolf D, Malchow H, Safdi M, Feagan B, Olson A, Hanauer<br />
S. Treatment of Crohn’s disease: response to Remicade (infliximab) in the<br />
Accent I trial through week 54. Am J Gastroenterol 2001; 96: S303<br />
85. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand<br />
RA, Podolsky DK et al. Infliximab for the treatment of fistulas in patients with<br />
with Crohn’s disease. N Engl J Med 1999; 340:1398-405<br />
86. Baert FJ, D'Haens R, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes<br />
K, Rutgeerts PJ TNF-α antibody (Infliximab) therapy profoundly downregulates<br />
the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116:<br />
22-28<br />
87. Hanauer S, Rutgeerts P, Targan S, Kam L, Present D, Mayer L et al.<br />
Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year<br />
interval without treatment. Gastroenterology 1999; 116: A731<br />
88. Bickston SJ, Lichtenstein GR, Arsenau KO, Cohen RB, Compinelli F The<br />
relationship between infliximab treatment and limphoma in Crohn's disease.<br />
Gastroenterology 1999; 117: 1433-1437<br />
89. Sachmechian A, Vasiliauskas E, Abreu M, Binder S, Papadakis K,<br />
Schaible T, Targan S, Kam L Malignancy following Remicade therapy:<br />
incidence and characteristics. Gastroenterology 2001; 120; A-619.<br />
90. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J,<br />
Schwieterman WD et al. Tubercolosis associated with infliximab, a tumor<br />
necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.<br />
91. Wrris A, Bjorneklett A, Gaustad P Invasive pulmonary aspergillosis<br />
associated with infliximab therapy. N Engl J Med 2001; 344: 1099-1100.<br />
92. American Thoracic Society. Targeted tubercolin testing and treatment of<br />
latent tubercolosis infection. Am J Respir Crit Care Med 2000; 161: S221-<br />
S247.<br />
81